Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
about
Biomarker development in MET-targeted therapyNF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerExpression of MET in circulating tumor cells correlates with expression in tumor tissue from advanced-stage lung cancer patients89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development."Companion diagnostics": has their time come and gone?Prognostic value of MET protein overexpression and gene amplification in locoregionally advanced nasopharyngeal carcinoma.PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational studyMET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations.Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET.MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell KillingProgress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.MET/HGF pathway in multiple myeloma: from diagnosis to targeted therapy?Prognostic and predictive value of MET deregulation in non-small cell lung cancerPromise and challenges on the horizon of MET-targeted cancer therapeuticsDual-receptor (EGFR and c-MET) inhibition by tumor-suppressive miR-1 and miR-206 in head and neck squamous cell carcinoma.Preclinical and clinical evaluation of MET functions in cancer cells and in the tumor stroma.Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.The Therapeutic Potential of Targeting the HGF/cMET Axis in Ovarian Cancer.MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Association of cancer metabolism-related proteins with oral carcinogenesis - indications for chemoprevention and metabolic sensitizing of oral squamous cell carcinoma?Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.HGF and NRG1 protein expression are not poor prognostic markers in surgically resected lung adenocarcinoma.A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patientsClinicopathological and prognostic significance of c-Met overexpression in breast cancer.PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition.Combination MET- and EGFR-directed therapy in MET-overexpressing non-small cell lung cancers: time to move on to better biomarkers?Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancerHigh c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.PD-L1 immunohistochemistry for non-small cell lung carcinoma: which strategy should be adopted?KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment.Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients?
P2860
Q26751332-F28EF273-F284-418D-9403-C5BF4AAE01DCQ28259999-60697B02-66A2-4581-9297-947994473A4BQ33688558-68E8D928-0B14-4207-9224-A3AE7AA5CBBDQ33841490-584DF7CF-DD2F-4631-B540-573EC52F6D33Q33917507-127D5CF2-3B8E-4993-98CA-FFB32CDBA1F3Q34135548-5B7870B3-5B90-49C2-990A-7B7F7D95B516Q35955290-962F4E1B-BDFD-4D20-A2DC-0D2EF11EDCCAQ36050773-868302B9-B75A-4574-9C14-1B1CDC425EDEQ36140765-C3CAD8C5-5051-4647-A981-3CA1DAC8C8D4Q37221902-3BE44834-7BF7-412D-8711-DC66D46FEB82Q37346559-3EFFEDBB-0743-4048-A256-AD7A1FB5482EQ37702041-09111999-9792-45A2-840F-7CCA4C1C5A8AQ37710498-2029AE95-C117-4B14-91B4-C9BD47E80FE7Q37739477-78B19895-B177-4AA5-8D63-BBAD5A3EE9E2Q37743107-1F75C5F2-4686-462A-9BEE-6B0B3D062DC6Q38383859-833EDAE8-17DD-4C3E-9EAE-C67396B3D1B5Q38476204-5066B6DA-93EF-4EF7-BA2F-0AA1FF48E5EAQ38493294-E3B99F16-714C-45C0-A152-7237C280E0DAQ38502350-2B478E74-7841-4360-9801-9555DEB2CD74Q38771636-75962892-E660-413D-A110-C7301490F505Q38782345-62ECE383-A544-4158-91C7-04F1C8A3B82FQ38799845-45BEAE6A-8B56-4903-B44F-5790D1CC887EQ38824065-9CD16176-3361-463C-9742-93FD8C7BA8F6Q38832652-B3DE544F-47B6-4268-9B5C-180016FB0B24Q38856729-2D7EC216-FE89-47D6-A25A-F6FF353EFC7EQ38973075-45B86CF6-3469-414F-AAB6-84BB6DA23A33Q39220897-8853B9DD-A116-433E-998B-DB51A618F911Q40867329-4336341A-382E-468A-AA3E-E1B17FECCB6DQ41045405-287CFDF9-20A0-453B-98CA-9A94FF19999CQ41340872-D5F979E8-1580-4728-A5ED-5A0FFD9C3EC6Q41344857-6A068974-4ABC-4D10-8F95-7CD94C6195A1Q41994295-B11824EF-2490-4AA8-8D2B-44B40BD5B961Q42332361-1CD0C653-EF4C-46C9-A7BF-0D04420E04C8Q42700876-0CB2B18C-684B-4C6A-8FE1-BDD69A5CE80AQ43521896-300775A4-D029-4DDA-B640-FEC257D9D443Q48620065-1DEBF4AD-5DE3-4248-9601-F9623E8863EDQ49887897-85EF0D3F-E51C-408E-AE8F-54F8B5F88B2BQ50985091-FB05CFE1-15C8-41B9-A32A-54E051FF898CQ53878549-8E2A81BD-BF83-410F-90D0-0028C0F43E01Q55318335-6BCDA5D4-EA3B-4EEE-9B5C-C9E6C5BA07F3
P2860
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Biomarker analyses from a plac ...... predictive of patient benefit.
@ast
Biomarker analyses from a plac ...... predictive of patient benefit.
@en
type
label
Biomarker analyses from a plac ...... predictive of patient benefit.
@ast
Biomarker analyses from a plac ...... predictive of patient benefit.
@en
prefLabel
Biomarker analyses from a plac ...... predictive of patient benefit.
@ast
Biomarker analyses from a plac ...... predictive of patient benefit.
@en
P2093
P2860
P921
P1476
Biomarker analyses from a plac ...... predictive of patient benefit.
@en
P2093
Ajay Pandita
Amy Peterson
David S Shames
Elicia Penuel
Ellen Filvaroff
Hartmut Koeppen
Jenny Huang
Jiping Zha
Linda Rangell
P2860
P304
P356
10.1158/1078-0432.CCR-13-1836
P407
P577
2014-03-31T00:00:00Z